English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/166072
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

AutorLópez-Rodríguez, Rosario; Pérez-Pampin, Eva; Márquez, Ana; Blanco, Francisco J. ; Joven, Beatriz; Carreira, P.; Ferrer, Miguel Angel; Cáliz, Rafael; Valor, Lara; Narváez, J.; Cañete, Juan D.; Ordoñez, María del Carmen; Manrique-Arija, Sara; Vasilopoulos, Yiannis; Balsa, Alejandro; Pascual-Salcedo, Dora; Moreno-Ramos, Manuel J.; Alegre-Sancho, Juan José; Navarro-Sarabia, Federico; Moreira, Virginia; García-Portales, Rosa; Raya, Enrique; Magro-Checa, Cesar; Martín, J.; Gómez-Reino, Juan J.; González, Antonio
Fecha de publicación7-may-2018
EditorPublic Library of Science
CitaciónPLoS ONE
ResumenGenetic biomarkers are sought to personalize treatment of patients with rheumatoid arthritis (RA), given their variable response to TNF inhibitors (TNFi). However, no genetic biomaker is yet sufficiently validated. Here, we report a validation study of 18 previously reported genetic biomarkers, including 11 from GWAS of response to TNFi. The validation was attempted in 581 patients with RA that had not been treated with biologic antirheumatic drugs previously. Their response to TNFi was evaluated at 3, 6 and 12 months in two ways: change in the DAS28 measure of disease activity, and according to the EULAR criteria for response to antirheumatic drugs. Association of these parameters with the genotypes, obtained by PCR amplification followed by single-base extension, was tested with regression analysis. These analyses were adjusted for baseline DAS28, sex, and the specific TNFi. However, none of the proposed biomarkers was validated, as none showed association with response to TNFi in our study, even at the time of assessment and with the outcome that showed the most significant result in previous studies. These negative results are notable because this was the first independent validation study for 12 of the biomarkers, and because they indicate that prudence is needed in the interpretation of the proposed biomarkers of response to TNFi even when they are supported by very low p values. The results also emphasize the requirement of independent replication for validation, and the need to search protocols that could increase reproducibility of the biomarkers of response to TNFi.
DescripciónSupporting information:S1 Text. Information on selected previous studies and compatibility with the current study. It includes two tables. Table A: List of SNPs selected for this study with references and the corresponding quality control results in the current study. Table B: Characteristics of the patients included in previous studies compared with the current study. https://doi.org/10.1371/journal.pone.0196793.s001 (DOCX) S1 Dataset. Raw data with all the variables and patients considered in this study. https://doi.org/10.1371/journal.pone.0196793.s002 (XLSX)
Versión del editorhttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196793#sec011
URIhttp://hdl.handle.net/10261/166072
E-ISSN1932-6203
Aparece en las colecciones: (IPBLN) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
journal.pone.0196793.pdfResearch article863,27 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.